This study focuses on patients with breast cancer that is hormone receptor-positive and HER2-negative. The research examines how the medication tamoxifen, which is used to treat breast cancer, works in patients before they undergo surgery. Tamoxifen is taken as a tablet by mouth and belongs to a group of medications called oncolytic agents that help fight cancer.
The main purpose of this research is to understand how quickly tamoxifen becomes effective in the body and how it affects certain markers in the tumor tissue. The study will investigate whether a shorter treatment period of three weeks can be as effective as the standard twelve-week treatment period. During the study, participants will receive tamoxifen tablets daily, with a maximum daily dose of 40 mg.
The research involves taking small samples of tumor tissue to measure a protein called Ki67, which helps determine how fast cancer cells are growing. The study will also measure levels of endoxifen (a substance that tamoxifen is converted into in the body) and monitor how the treatment affects hormone levels in the blood. Participants will be asked to complete questionnaires about their symptoms and overall well-being during the treatment period.



The Netherlands